

Towards a vaccine against AIDS

Vincent Vieillard, Nathalie Dereuddre-Bosquet, Aurélien Corneau, Isabelle Mangeot-Méderle, Hugues Fausther-Bovendo, Roger Le Grand, Patrice Debre

► **To cite this version:**

Vincent Vieillard, Nathalie Dereuddre-Bosquet, Aurélien Corneau, Isabelle Mangeot-Méderle, Hugues Fausther-Bovendo, et al.. Towards a vaccine against AIDS. 16th International Symposium on HIV and Emerging Infectious Diseases, Mar 2010, Marseille, France. BioMed Central, 7 (Suppl 1), pp.I32, 2010, Retrovirology. <10.1186/1742-4690-7-S1-I32>. <inserm-00663751>

HAL Id: inserm-00663751

<http://www.hal.inserm.fr/inserm-00663751>

Submitted on 27 Jan 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



INVITED SPEAKER PRESENTATION

Open Access

Towards a vaccine against AIDS

Vincent Vieillard^{1,2}, Nathalie Dereuddre-Bosquet³, Aurélien Corneau³, Isabelle Mangeot-Méderle³, Hugues Fausther-Bovendo^{1,2}, Roger Le Grand³, Patrice Debre^{1,2*}

From 16th International Symposium on HIV and Emerging Infectious Diseases
Marseille, France. 24-26 March 2010

Aim

The CD4 depletion in the chronic phase of HIV infection is mostly due to the loss of uninfected cells. We previously showed that this loss was related to the expression of NKp44L, a cellular ligand of the natural cytotoxicity receptor NKp44, which renders CD4 cells sensitive to NK killing. NKp44L is specially induced by the highly conserved 3S motif of the HIV-1 gp41 envelope protein. We also have shown that NKp44L is present on bystander non-infected CD4 cells, but absent from HIV-infected cells, through a Nef-dependent mechanism. In this study we sought to determine whether the loss of uninfected bystander CD4 cells could be prevented by a 3S therapeutic immunization in a macaque model chronically infected with SHIV162P3.

Methods

Ten cynomolgus macaques were chronically infected with SHIV162P3. Seven months after infection, the animals were primed/boosted in IFA with 3S-KLH or free KLH, as control. Lymphocyte samples and sera were periodically tested, while secondary lymphoid organs after euthanasia, at 7 months post-immunization.

Results

We discovered that immunization with 3S-KLH, significantly decreases of NKp44L expression on CD4 cells, and NK cells cytotoxicity against autologous CD4 cells, when compared to infected group with free KLH-immunization. Interestingly, the frequency of CD4 central memory T cells from immunized animals remains stable, while decreasing in the control group. Finally, in lymphoid organs, including spleen, lymph node and gut, a significant decrease of the cell-activation and the caspase-3 dependent apoptosis was observed in macaques immunized by 3S-KLH, as compared to control.

Discussion

These results emphasize the deleterious role of NK cells on CD4 depletion and demonstrate for the first time, its prevention by a therapeutic vaccine, which should also inhibits and/or delay disease evolution to AIDS.

Author details

¹INSERM UMR-S 945 Paris, France. ²Université Paris-6 Paris, France. ³CEA, Division Immuno-Virology Fontenay-aux-roses, France.

Published: 11 May 2010

doi:10.1186/1742-4690-7-S1-I32

Cite this article as: Vieillard et al.: Towards a vaccine against AIDS. *Retrovirology* 2010 **7**(Suppl 1):132.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹INSERM UMR-S 945 Paris, France